KYORIN Pharmaceutical (4569) FY2026 Q3 Earnings Report

Quick View

Executive Summary

FY2026 Q3 results show Kyorin Pharmaceutical achieving revenue of 92.5B yen (YoY +3.6%), operating income of 4.6B yen (YoY +47.9%), ordinary income of 5.1B yen (YoY +35.8%), and net income of 4.1B yen (YoY +68.9%). The significant profit improvement was driven by enhanced gross margins at 42.8% and contributions from non-operating gains including investment securities sales gains of 0.4B yen and dividend income of 0.5B yen. While revenue growth remains modest at 3.6%, operating profit expansion of 47.9% demonstrates improved cost management. However, the full-year forecast indicates operating income declining 51.5% YoY to 6.1B yen, suggesting Q3 results benefited from temporary factors. Financial position remains solid with current ratio of 413.9% and debt-to-capital ratio of 17.4%, though working capital efficiency shows significant deterioration with DSO at 178 days and inventory turnover at 182 days.

Key Metrics

[Profitability] ROE of 3.0% reflects limited return on equity despite profit improvement, with net profit margin at 4.5% and operating margin at 5.0% showing room for improvement relative to historical levels. Financial leverage of 1.40x remains conservative. Interest coverage ratio stands at 25.05x indicating strong debt servicing capability with interest expenses of 0.2B yen well covered by operating profit. The tax burden ratio of 0.746 and effective tax rate of 25.4% are within normal ranges. [Cash Quality] Cash and deposits of 14.0B yen provide coverage of 1.54x against short-term borrowings of 9.1B yen, indicating adequate liquidity for near-term obligations. Working capital efficiency has deteriorated significantly with DSO extending to 178 days, inventory turnover at 182 days, and cash conversion cycle of 575 days, suggesting substantial delays in cash realization from operations. [Investment Efficiency] Asset turnover of 0.476x demonstrates moderate asset utilization. ROIC metrics indicate returns below optimal levels given the extended working capital cycle. [Financial Health] Equity ratio of 71.5% reflects strong capitalization and conservative financial structure. Current ratio of 413.9% and quick ratio of 335.3% indicate robust short-term liquidity. Total interest-bearing debt of 29.2B yen against equity of 138.9B yen results in debt-to-equity ratio of 0.21x, maintaining low leverage. Debt-to-capital ratio of 17.4% confirms conservative capital structure with ample debt capacity.

Cash Flow Analysis

Cash and deposits of 14.0B yen represent a baseline liquidity position adequate for covering short-term debt obligations of 9.1B yen with 1.54x coverage. The balance sheet reveals significant working capital challenges with accounts receivable of 45.2B yen and inventories of 26.4B yen representing substantial capital tied up in operations. Accounts payable of 23.8B yen provides partial offset through supplier credit. The extended DSO of 178 days and inventory days of 182 days indicate prolonged conversion cycles from operations to cash, suggesting either collection difficulties, generous customer payment terms, or potential demand forecasting issues. Total current assets of 139.2B yen against current liabilities of 33.6B yen demonstrate strong liquidity cushion despite working capital inefficiencies. The reduction in treasury stock book value from 17.3B yen to 5.9B yen during the period suggests potential share cancellation or disposal activities, representing a shift in capital allocation policy. With dividend payout ratio calculated at approximately 83.0% based on quarterly earnings run-rate, cash generation capability becomes critical for sustaining distributions, though current liquidity position provides near-term support.

Earnings Quality

Ordinary income of 5.1B yen versus operating income of 4.6B yen shows net non-operating contribution of approximately 0.5B yen, comprising primarily dividend income of 0.5B yen and minimal net financial costs given interest expenses of 0.2B yen. Additionally, extraordinary gains from investment securities sales of 0.4B yen contributed to net income expansion. Non-operating and extraordinary items represent approximately 1.0% of revenue from financial income and securities gains, indicating partial reliance on investment-related returns beyond core operations. The substantial 68.9% increase in net income compared to 47.9% operating income growth reflects both non-operating gains and tax effects supporting bottom-line performance. Working capital quality indicators raise concerns as extended receivables turnover of 178 days and inventory turnover of 182 days significantly exceed typical pharmaceutical industry norms, suggesting either business model characteristics or operational efficiency challenges. The cash conversion cycle of 575 days indicates nearly 1.6 years required to convert investments in operations back to cash, which could signal earnings quality issues if accounts receivable or inventory contain aged or impaired items. Without operating cash flow data disclosed for the quarter, direct verification of cash-backed earnings remains limited, though the deteriorating working capital metrics warrant attention regarding the sustainability of reported profits.

Risk Factors

1. Working capital deterioration poses significant cash generation risk, with DSO of 178 days and inventory turnover of 182 days creating cash conversion cycle of 575 days, substantially constraining liquidity generation despite reported profit improvements and potentially masking collection or inventory obsolescence issues.

2. High dividend payout ratio of approximately 83.0% based on quarterly earnings run-rate limits financial flexibility and internal capital accumulation, creating sustainability concerns if operating cash flow generation fails to improve alongside working capital efficiency deterioration.

3. Revenue growth constraints evident in modest 3.6% YoY increase and full-year forecast indicating 2.4% revenue decline suggest limited top-line momentum, while full-year operating income guidance of 6.1B yen represents 51.5% decline YoY, indicating Q3 profit expansion may derive from temporary factors including investment securities gains rather than sustainable operational improvements.

Industry Benchmark (Reference - Proprietary Data)

[Industry Position] (Reference - Proprietary Analysis)

Profitability: Operating margin 5.0% substantially exceeds industry median of -218.2% (Q3 2025), indicating Kyorin maintains positive operational profitability while many pharmaceutical peers report significant losses. Net profit margin of 4.5% similarly outperforms industry median of -216.8%, positioning the company among profitable operators. ROE of 3.0% significantly exceeds industry median of -35.8%, though absolute ROE level remains modest. ROA of 2.1% compares favorably to industry median of -23.9%.

Financial Health: Equity ratio of 71.5% aligns closely with industry median of 67.8% (IQR: 62.1%-79.1%), indicating comparable capital structure conservatism. Current ratio of 413.9% falls below industry median of 662% but remains within healthy liquidity range. Financial leverage of 1.40x approximates industry median of 1.47x, confirming typical sector capitalization structure.

Efficiency: Asset turnover of 0.476x substantially exceeds industry median of 0.17x, demonstrating superior asset utilization relative to peers. However, receivables turnover of 178 days extends beyond industry median of 151.55 days, and inventory turnover of 182 days compares unfavorably to median of 281.61 days when adjusted for direction, indicating working capital efficiency challenges. Operating working capital turnover cycle substantially exceeds industry median of 148.78 days, confirming relative inefficiency in working capital management.

Growth: Revenue growth of 3.6% YoY outperforms industry median decline of -12.5%, positioning Kyorin among growth-oriented pharmaceutical companies in a contracting sector environment.

(Industry: Pharmaceutical sector, N=13 companies for most metrics, Comparison period: Q3 2025, Source: Proprietary analysis)

Key Takeaways from Earnings

First, the significant profit margin improvement with operating income growth of 47.9% outpacing revenue growth of 3.6% demonstrates effective operational leverage and cost management, though sustainability requires monitoring given full-year guidance indicating 51.5% operating income decline, suggesting Q3 benefited from temporary factors including 0.4B yen investment securities gains. The company maintains positive profitability substantially outperforming pharmaceutical industry peers where median operating and net margins remain deeply negative, indicating relative competitive positioning strength or business model differentiation.

Second, working capital efficiency deterioration represents the most critical operational concern, with cash conversion cycle of 575 days and receivables turnover of 178 days signaling substantial delays in converting sales to cash. This working capital intensity substantially exceeds pharmaceutical industry norms and creates latent cash flow pressure despite reported profit improvements, requiring operational process improvements in collections and inventory management to unlock trapped capital.

Third, the combination of high dividend payout ratio at 83.0% and robust financial position with equity ratio of 71.5%, current ratio of 413.9%, and interest coverage of 25.05x presents mixed signals: while near-term dividend sustainability appears supported by strong balance sheet liquidity, the elevated payout ratio limits capital reinvestment flexibility and creates vulnerability if operating cash generation fails to improve alongside working capital efficiency challenges.

---

This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was operationally improved, with profit growth materially outpacing modest sales growth, although capital efficiency and working-capital intensity remain weak. Nine-month revenue rose 3.6% YoY to ¥92.46bn. Operating income increased 47.9% YoY to ¥4.61bn, substantially faster than revenue. Ordinary income rose 35.8% to ¥5.10bn. Net income increased 68.9% to ¥4.12bn, or ¥71.71 per share. The gross margin was 42.8%, down approximately 55bp from 43.3% in the prior-year period. However, the SG&A-to-sales ratio improved by approximately 205bp to 37.8% from 39.8%. This SG&A discipline more than offset the gross-margin contraction and lifted the operating margin by approximately 150bp to 5.0%. The net margin expanded by approximately 173bp to 4.5%, benefiting both from higher operating profit and non-recurring gains. Pre-tax profit included a net extraordinary gain of ¥0.43bn, primarily a ¥0.37bn gain on sales of investment securities and a ¥0.10bn subsidy. Dividend income of ¥0.50bn was also a meaningful contributor to non-operating income, indicating that earnings retain some dependence on investment returns rather than solely operating activities. The balance sheet remains highly liquid, with a 413.9% current ratio and ¥105.55bn of working capital. Leverage is controlled, with debt-to-equity of 0.40x and interest coverage of 25.05x. Nevertheless, reported annualized ROE is only 4.0% and ROIC is 3.0%, demonstrating that the sizable equity base and invested capital are not yet generating attractive returns. Receivables of ¥45.16bn and inventories of ¥26.44bn are substantial relative to nine-month revenue and are reflected in elevated collection, inventory, and cash-conversion-cycle alerts. The company has achieved 72.8% of its full-year revenue forecast, 75.6% of its operating-income forecast, and 85.8% of its net-income forecast after nine months. This profile implies that the operating-profit target is broadly on track, while net-income progress is ahead of the standard 75% pace partly because of extraordinary gains. The principal forward implication is that sustaining margin improvement while reducing working-capital intensity and improving ROIC will be more important than further balance-sheet expansion.

Profitability Analysis

Annualized DuPont ROE is 4.0%, decomposed into a 4.5% net profit margin, 0.635x asset turnover, and 1.40x financial leverage. The low ROE is principally explained by weak margins and slow asset turnover, rather than insufficient leverage. Financial leverage is conservative and contributes modestly to returns, consistent with total equity of ¥138.87bn funding 71.5% of total assets. Asset turnover of 0.635x indicates that the company generates limited sales from its asset base, particularly given receivables, inventories, property, plant and equipment, and investment securities. The most favorable YoY profitability change was operating-margin expansion to 5.0% from approximately 3.5%. Although revenue increased only 3.6%, operating income rose 47.9%, demonstrating positive operating leverage from SG&A containment. SG&A declined 1.8% YoY to ¥34.92bn while revenue increased, reducing the SG&A ratio to 37.8%. Gross profit increased 1.7% to ¥39.53bn, slower than sales growth, and the gross-margin decline suggests that the operating improvement did not come from gross-margin expansion. The EBIT margin of 5.0% remains at the boundary of the low-operating-efficiency alert and well below the 8-15% benchmark for a strong operating profile. The ROIC alert of 3.0% reinforces that the margin improvement has not yet translated into adequate returns on the capital employed in the business. The tax burden was normal at 0.746, corresponding to a 25.4% effective tax rate. The interest burden exceeded 1.0x because pre-tax income benefited from items below EBIT, including investment-related and extraordinary income; it should not be interpreted as a structural operating-return advantage. Net income growth of 68.9% exceeded operating-income growth because the current period recorded net extraordinary gains, whereas the prior period included extraordinary losses. Therefore, the improvement in recurring profitability is solid but less pronounced than the headline net-income growth.

Growth Assessment

Revenue growth of 3.6% to ¥92.46bn represents moderate top-line expansion. The stronger 47.9% increase in operating income indicates that the current earnings recovery is primarily driven by cost efficiency rather than rapid revenue acceleration. The Q3 cumulative operating margin of 5.0% supports the full-year operating-income forecast of ¥6.10bn, as the company has already achieved 75.6% of that target versus the standard 75% nine-month progress rate. Revenue progress is slightly below the standard pace at 72.8% of the ¥127.00bn full-year forecast, implying required fourth-quarter revenue of ¥34.54bn. Required fourth-quarter operating income is ¥1.49bn, equivalent to a 4.3% implied fourth-quarter operating margin, below the nine-month margin and therefore achievable if current cost control is retained. Net-income progress is 85.8% of the ¥4.80bn forecast, above the standard pace, but its lead over plan is partly supported by non-recurring investment-security gains and subsidies. The full-year forecast implies fourth-quarter net income of ¥0.68bn, materially below the nine-month run rate. The forecast calls for full-year sales to decline 2.4% YoY and operating income to decline 51.5% YoY, making the prospective year-on-year comparison demanding despite the current cumulative progress. The company should therefore be assessed on its ability to preserve the SG&A ratio improvement and convert revenue growth into recurring operating income rather than on the elevated Q3 net-income growth rate. For a pharmaceutical company, commercialization execution, reimbursement and drug-pricing pressure, generic competition, and development outcomes remain central determinants of revenue durability. The 5.0% operating margin also leaves limited room to absorb pricing pressure or sales-mix deterioration.

Financial Health

Financial health is strong from a liquidity and solvency perspective. Current assets of ¥139.17bn exceeded current liabilities of ¥33.63bn by ¥105.55bn, producing a current ratio of 413.9%. The quick ratio of 335.3% indicates that liquidity remains robust even before relying on inventory conversion. Cash and deposits were ¥14.03bn, while short-term loans were ¥9.10bn, resulting in cash coverage of 1.54x for short-term debt. The short-term debt ratio was 31.2% of interest-bearing debt, and the company has sufficient current assets to cover short-term funding obligations without a maturity mismatch. Total interest-bearing debt was ¥29.20bn, comprising ¥9.10bn of short-term loans and ¥20.10bn of long-term loans. Debt-to-equity of 0.40x and debt-to-capital of 17.4% are conservative and well below risk thresholds. Interest coverage of 25.05x provides substantial protection against financing-cost increases. Total liabilities declined by ¥1.94bn YoY to ¥55.40bn, while equity increased by ¥2.58bn to ¥138.87bn. Treasury stock decreased by ¥11.42bn YoY to negative ¥5.93bn, a 65.8% reduction in the treasury-stock balance. This change materially supports reported equity and indicates a significant capital action affecting the treasury-share account; investors should monitor the associated capital-allocation rationale and any impact on per-share metrics. Receivables accounted for 23.2% of total assets, inventories 13.6%, and investment securities 9.7%, highlighting that a meaningful portion of the asset base is tied up outside cash. Intangible assets were only 2.2% of total assets, limiting balance-sheet concentration in acquired intangible assets.

Notable B/S Changes

Treasury stock: +¥11.42bn reduction in the negative balance (-¥17.35bn to -¥5.93bn; +65.8%) - significant treasury-share capital action supported the equity base; monitor implications for future capital allocation and per-share measures. Inventories: +¥3.88bn (+17.2%) to ¥26.44bn - inventory build coincides with elevated inventory-day alerts and heightens monitoring needs for turnover, demand alignment, and obsolescence. Work in process: +¥5.83bn (+44.5%) to ¥18.94bn - sizable increase in production-stage inventory increases capital tied up in manufacturing and may contribute to the long cash conversion cycle. Raw materials: -¥5.30bn (-17.6%) to ¥24.76bn - lower raw-material holdings partly offset higher work in process and finished goods, suggesting a shift in the inventory mix toward later production stages. Accounts payable: -¥2.89bn (-18.6%) to ¥12.63bn - lower supplier financing can add to working-capital funding needs when combined with higher inventory. Provision for bonuses: -¥1.13bn (-51.0%) to ¥10.92bn - the reduction lowered current liabilities and should be monitored for any effect on future personnel-cost timing. Investment securities: -¥1.14bn (-5.7%) to ¥18.91bn - the balance decline is consistent with the ¥0.37bn gain on sales of investment securities recorded in extraordinary income.

Cash Flow Quality

The principal earnings-quality issue is the heavy working-capital commitment indicated by the quality alerts. Receivable days of 134 days are well above the 60-day alert threshold, suggesting slow collection and a high level of sales capital tied up in customer balances. Inventory days are reported at 363 days under one measure and 137 days under another; both readings exceed their respective alert thresholds and point to elevated stockholding requirements. The long cash conversion cycle of 431 days is particularly significant because it combines slow receivable conversion with high inventory intensity. This profile raises the risk that accounting earnings may not convert into distributable cash at the same pace, especially during periods of sales deceleration. Finished goods were ¥26.44bn, while work in process was ¥18.94bn and raw materials were ¥24.76bn, underscoring the manufacturing working-capital burden. Inventories increased ¥3.88bn YoY, or 17.2%, while receivables decreased ¥2.43bn, or 5.1%. The reduction in receivables is constructive, but it has not eliminated the high-Days Sales Outstanding concern. The inventory increase should be monitored for demand support, production planning, product-mix effects, and potential obsolescence risk. Reported net income was also supported by ¥0.43bn of net extraordinary gains before tax, mainly gains on investment securities, which are not a recurring source of operating cash generation. Dividend income of ¥0.50bn further lifts earnings below operating income and should be distinguished from cash generated by pharmaceutical operations. Accordingly, the quality of the earnings improvement rests on continued operating-margin recovery and improved working-capital conversion rather than on investment-related gains.

Dividend Sustainability

The interim dividend was ¥20.00 per share. Based on nine-month net income of ¥4.12bn, the calculated interim payout ratio is 29.1%. The full-year dividend forecast is ¥57.00 per share against forecast EPS of ¥83.55, implying a dividend-only payout ratio of approximately 68.2%. This is above the stated sub-60% sustainability benchmark, but remains below 100% and is supported by the company’s substantial equity base and strong liquidity. The implied full-year cash dividend requirement is approximately ¥3.27bn based on 57.45 million average shares. That amount would represent approximately 68% of the ¥4.80bn full-year net-income forecast. The dividend outlook is therefore financially manageable under the earnings forecast, but it leaves a narrower earnings retention margin than the current interim payout ratio suggests. The key determinant of sustainability is whether recurring operating profits and working-capital conversion can support distributions without dependence on security-sale gains or balance-sheet cash resources. The ¥11.42bn reduction in treasury stock also makes capital-allocation discipline relevant; dividends should be evaluated alongside any future share-related capital actions as total return rather than payout alone.

Risk Assessment

Business risks include Pharmaceutical pricing, reimbursement reform, and generic competition could pressure the 42.8% gross margin and limit the ability to sustain the 5.0% operating margin., Clinical-development, regulatory, manufacturing, and product-lifecycle risks can affect pharmaceutical revenue durability and cost absorption., Revenue growth was only 3.6%, so the earnings recovery depends materially on SG&A efficiency; renewed selling or administrative cost growth could reverse operating leverage., The high inventory-days alerts of 363 days and 137 days indicate a risk of excess stock, inventory obsolescence, or production-demand mismatch..

Financial risks include Receivable days of 134 days exceed the 60-day alert level, creating collection-timing and customer-credit exposure., A 431-day cash conversion cycle indicates that a large amount of capital is tied up in operations and may constrain cash generation during weaker demand conditions., ROIC of 3.0% and annualized ROE of 4.0% are below return thresholds, creating a risk of persistently low shareholder-value creation despite a strong balance sheet., Net income includes non-recurring gains on sales of investment securities and subsidies, which may not recur in future periods..

Key concerns include LOW_OPERATING_EFFICIENCY: The 5.0% EBIT margin is at the alert threshold and remains below a robust pharmaceutical operating-profitability range. The recent margin improvement reflects SG&A reduction, but the lower gross margin means the recovery remains sensitive to pricing and cost mix., CAPITAL_EFFICIENCY: ROIC of 3.0% is below the 5% warning threshold. The company is conservatively financed, so the issue is operating return and asset productivity rather than excessive leverage., HIGH_RECEIVABLE_DAYS: DSO of 134 days is more than twice the 60-day alert level. This increases capital lock-up and means continued receivable reduction is important for earnings conversion., HIGH_INVENTORY_DAYS: The 363-day inventory-days measure is substantially above the 90-day threshold. This is a material working-capital and obsolescence consideration for a manufacturer with pharmaceutical inventory., LONG_CCC: The 431-day cash conversion cycle is far above the 120-day alert threshold. The combination of elevated DSO and inventory intensity can make operating cash generation volatile even when reported profits improve., HIGH_INVENTORY_DAYS: The separately reported 137-day measure is also above its 60-day threshold. Regardless of measurement convention, inventory turnover requires improvement..

Investment Implications

Key takeaways include Operating income increased 47.9% YoY to ¥4.61bn as SG&A fell 1.8% despite 3.6% revenue growth., Operating-margin expansion of approximately 150bp to 5.0% is encouraging, but remains low in absolute terms., Net-income growth of 68.9% was amplified by a ¥0.43bn net extraordinary gain before tax, led by investment-security sales., Liquidity and debt service capacity are strong, with a 413.9% current ratio, 0.40x debt-to-equity, and 25.05x interest coverage., Capital efficiency and working-capital management remain the core financial issues, with 3.0% ROIC, 4.0% annualized ROE, 134-day DSO, and a 431-day cash conversion cycle., Full-year operating-income progress of 75.6% is aligned with the normal nine-month pace, while 85.8% net-income progress should be interpreted in light of non-recurring gains..

Metrics to watch include Operating margin and SG&A-to-sales ratio, Gross margin and pricing/product-mix effects, Receivable days and receivables balance, Inventory days, finished-goods balance, and inventory obsolescence exposure, Cash conversion cycle, ROIC and annualized ROE, Recurring ordinary and operating income excluding investment-security gains, Delivery versus the ¥127.00bn revenue and ¥6.10bn operating-income full-year forecasts, Dividend coverage relative to recurring earnings and cash generation.

Regarding relative positioning, The company is positioned as financially conservative, with unusually strong liquidity and manageable debt relative to equity, but its return profile is weak relative to standard profitability and capital-efficiency benchmarks. The current earnings trend shows improving cost discipline, yet the combination of a 5.0% operating margin, 3.0% ROIC, and very long working-capital cycle indicates that balance-sheet strength has not yet translated into strong operating returns.